Table 4 Cox regression analysis of overall survival.

From: Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Variable

Univariate analysis

Multivariate analysis

HR

95% CI

p value

HR

95% CI

p value

Age ≥ 65

1.33

1.05–1.69

0.019

1.19

0.92–1.54

0.184

ECOG 0, 1

0.38

0.29–0.50

 < 0.001

0.41

0.31–0.56

 < 0.001

Male

1.07

0.84–1.36

0.576

–

–

–

Current/ex-smoker

1.16

0.88–1.52

0.290

–

–

–

EGFR L858R

1.32

1.01–1.72

0.044

1.46

1.13–1.88

0.003

Afatinib treatment

0.69

0.54– 0.87

0.002

0.98

0.75–1.28

0.893

Brain metastasis

1.26

0.99–1.60

0.063

1.10

0.86–1.42

0.431

Liver metastasis

1.47

1.06–2.04

0.022

1.36

0.97–1.92

0.072

Back to article page